This white paper examines the significant tuberculosis burden across Asia Pacific, where Southeast Asia represents a large share of global TB cases and countries such as India, Indonesia, and the Philippines account for a substantial portion of incidence. It reviews WHO-recommended treatment regimens for drug-susceptible and MDR/RR-TB and analyzes patient-, treatment-, and health system–related challenges affecting clinical trial execution, including stigma, economic hardship, adherence barriers, and infrastructure gaps. The paper highlights digital adherence technologies, thoughtful country and site selection, and strong regulatory alignment as key enablers of successful TB trials. It concludes that Asia Pacific’s large patient population and growing trial maturity position it as a critic

Join for free to read